Catalog No. | HY257146 |
---|---|
Description | Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab is an investigational, T-cell bispecific antibody with a distinctive design that features 2 Fab arms for binding CD20 on B cells, along with 1 Fab arm for binding CD3 on T cells. The CD3 binding arm is fused directly to one of the CD20-binding arms in a head-to-tail fashion via a short flexible linker. |
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Humanized |
Isotype | IgG1-kappa-lambda |
Expression system | Mammalian Cells |
Species | Human |
Clonality | Monoclonal |
Target | B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
Concentration | 1.06 mg/ml |
Endotoxin level | Please contact with the lab for this information. |
Purity | >95% as determined by SDS-PAGE. |
Purification | Protein A/G purified from cell culture supernatant. |
Accession | P11836 & P07766 |
Form | Liquid |
Storage buffer | 0.01M PBS, pH 7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
Alternate Names | Bispecific, CD20-TCB (2:1), RG-6026, CAS: 2229047-91-8 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Detects CD3E in indirect ELISAs.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France